Chromosomal abnormalities in acute myeloid leukaemias;Anomalies chromosomiques dans les leucémies aiguës myéloïdes

Pathologie Biologie

Volumn 51, Issue 6, 2003, Pages 314-328

  Mugneret, F ^a   Callier, P ^a   Favre Audry, B ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

Acute myeloid leukaemia; Chromosomes; Cytogenetics; Karyotypes abnormalities

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; CHILD; CHROMOSOME 11Q; CHROMOSOME 16; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CORRELATION ANALYSIS; CYTOGENETICS; DIAGNOSTIC VALUE; FOLLOW UP; GENE DELETION; GENE FUNCTION; GENE REARRANGEMENT; GENE THERAPY; GENETIC IDENTIFICATION; HUMAN; IMMUNOPATHOLOGY; KARYOTYPE; LEUKEMOGENESIS; MORPHOLOGICAL ADAPTATION; PROGNOSIS; RANDOMIZATION; RELAPSE; REVIEW; RISK FACTOR;

EID: 0042862826     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(03)00114-7     Document Type: Article

References (145)

1. Fourth International Workshop on Chromosomes in Leukaemia 1982. Translocation (8;21)(q22;q22) in acute nonlymphocytic leukaemia. Cancer Genet Cytogenet 1984;11:284-7.
2. Berger R, Flandrin G, Bernheim A, le Coniat M, Vecchione D, Pacot A, et al. Cytogenetics studies on 519 consecutive de novo acute non lymphocytic leukaemias. Cancer Genet Cytogenet 1987;29:9-21.
3. Heim S, Mitelman F. Cancer Cytogenetics. 2nd edition. New York: Wiley-Liss INC.; 1995.
4. Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukaemia. Leukaemia 1995;9:1491-8.
5. Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP, et al. Chromosomal abnormalities in 478 children with acute myeloid leukaemia: clinical characteristics and treatment outcome in a Cooperative Pediatric Oncology Group Study - POG 8821. Blood 1999;94(11):3707-16.
6. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pre-treatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukaemia: results from CALGB 8461. Blood 2002;100:4325-36.
7. Cherif D, Berger R. Fluorescence in situ hybridization and cytogenetics of hemopoietic malignancies: new developments. Nouv Rev Fr Hematol 1993;35:45-7.
8. Cuneo A, Bigoni R, Cavazzini F, Bardi A, Roberti MG, Agostini P, et al. Incidence and significance of cryptic chromosome aberration detected by fluorescence in situ hybridization in acute myeloid leukaemia with normal karyotype. Leukaemia 2002;16(9):1745-51.
9. Frohling S, Skelin S, Liebisch C, Scholl C, Schlenk RF, Dohner H, et al. Acute Myeloid Leukaemia Study Group, Ulm. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukaemia. J Clin Oncol 2002 May 15;20(10):2480-5.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100(7):2292-302.
11. Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukaemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 2002;99(10):3517-23.
12. Slovak ML, Bedell V, Popplewell L, Arber DA, Schoch C, Slater R. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer 2002;33:379-94.
13. Heim S, Mitelman F. Cytogenetic analysis in the diagnosis of acute leukaemia. Cancer 1992;15:1701-9.
14. Nucifora G, Rowley JD. The AML1 and Eto genes in acute myeloid leukaemia with t(8;21). Leuk Lymphoma 1994;14:353-62.
15. Brunning RD, Matutes E, Borowitz M, Flandrin G, Head D, Vardiman J, et al. Acute leukaemias of ambiguous lineage. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours Pathology and genetics of tumours of heamatopoietic and lymphoid tissues. Lyon: IARC press,; 2001.
16. Groupe Français de Cytogénétique Hématologique. Acute myelogenous leukaemia with an (8;21) translocation. A report of 148 cases from the Groupe français de cytogéné tique hématologique. Cancer Genet Cytogenet 1990;44:169-79.
17. Schoch C, Haase D, Haferlach T, Gudat H, Büchner T, Freund M, et al. Fifty-one patients with acute myeloid leukaemia and translocation t(8;21)(q22;q22): and additional deletion in 9q is an adverse prognostic factor. Leukaemia 1996;10:1288-95.
18. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC/AML 10 trial. Blood 1998;92(7):2322-33.
19. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukaemia: overview report. Genes Chromosomes Cancer 2002;33:331-45.
20. Second MIC, Cooperative Study Group. Morphologic, Immunologic and cytogenetic (MIC) Working Classification of the Acute Myeloid Leukaemias. Cancer Genet Cytogenet 1988;30:1-15.
21. Langabeer SE, Grimwade D, Walker H, Rogers JR, Brunett AK, Goldstone AH, et al. A study to determine whether trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements of PML/RARα, AML1/Eto and CBFB/MYH11 respectively in acute myeloid leukaemia. Br J Haematol 1998;101:338-40.
22. Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, et al. Comparison of outcome in acute myelogenous leukaemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/Eto fusion transcript found only by PCR testing. Leukaemia 2001;15:57-61.
23. Rowe D, Cotterill SJ, Ross FM, Bunyan DJ, Vickers SJ, Bryon J, et al. Cytogenetically cryptic AML1-Eto and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. Br J Haematol 2000 Dec;111(4):1051-6.
24. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Anwar M. Karyotypic analysis predicts outcome of preremission and prostremission therapy in adult acute myeloid leukaemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96(13):4075-83.
25. Wiemels JL, Xiao Z, Buffler PA, Maja AT, Ma X, Dicks BM, et al. In utero origin of t(8;21) AML1-Eto translocations in childhood acute myeloid leukaemia. Blood 2002;99(10):3801-5.
26. Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB, et al. Backtracking leukaemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997;94:13950-4.
27. Wiemels JL, Cazzaniga G, Dianotti M, Eden OB, Addison GM, Masera G, et al. Prenatal origin of acute lymphoblastic leukaemia Children. Lancet 1999;354:1499-503.
28. De The H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A. Identification of a retinoic acid responsive element in the retinoic acid receptor beta-gene. Nature 1990;343:177-80.
29. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijr A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukaemia cases lacking the classic t(15;17): results of the European Working Party. Blood 2000;96(4):1297-308.
30. De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A. European APL Group. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000;111:801-6.
31. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukaemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:395-400.
32. Sainty D, Liso V, Cantù-Rajnoldi A, Head D, Mozziconacci MJ, Arnoulet C, et al. A new morphologic classification system for acute promyelocytic leukaemia distinguishes cases with underlying PLZF/Rara gene rearrangements. Blood 2000;96(4):1287-96.
33. Corey SJ, Locker J, Oliveri DR, Shekhter-Levin S, Redner RL, Penchansky L, et al. A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukaemia (APML) with atypical features. Leukaemia 1994;8:1350-3.
34. Brunel V, Sainty D, Carbuccia N, Arnoulet C, Costello R, Mozziconacci MJ, et al. Unbalanced translocation t(5;17) in an typical acute promyelocytic leukaemia. Genes Chromosomes Cancer 1995;14:307-12.
35. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukaemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996;87:882-6.
36. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor ct to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nature Genet 1997;17:109-13.
37. Arnould C, Philippe C, Bourdon V, Grégoire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription Stat5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukaemia. Hum Mol Genet 1999;8(9):1741-9.
38. Maurer AB, Wichmann C, Gross A, Kunkel H, Heinzel T, Ruthardt M, et al. The Stat5-RARα fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood 2002;99(8):2647-52.
39. Hayashi Y. The molecular genetics of recurring chromosome abnormalities in acute myeloid leukaemia. Semin Hematol 2000;4:368-80.
40. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukaemia 1995;9:965-71.
41. Wong KF, Kwong YL. Trisomy 22 in acute myeloid leukaemia: a marker for myeloid leukaemia with monocytic features and cytogenetically cryptic inversion 16. Cancer Genet Cytogenet 1999;109:131-3.
42. Van der Reijden BA, de Wit L, van der Poel S, Luiten EB, Lafage-Pochitaloff M, Dastugue N, et al. Identification of a novel CBFB-MYH11 transcript: implications for RT-PCR diagnosis. Hematol J 2001;2:206-9.
43. Pirc-Danoewinata H, Dauwerse HG, Konig M, Chudoba I, Mitterbauer M, Jager U, et al. CBFB-MYH11 fusion in a patient with AML-M4Eo and cytogenetically normal chromosomes 16. Genes Chromosomes Cancer 2000;29:186-91.
44. Berger R, Bernheim A, Weh HJ, Daniel MT, Flandrin G. Cytogenetic studies on acute monocytic leukaemia. Leuk Res 1980;4:119-27.
45. Hagemeijer A, Hahlen K, Abels J. Cytogenetic follow-up of patients with nonlymphocytic leukaemia. II. Acute nonlymphocytic leukaemia. Cancer Genet Cytogenet 1981;3:109-24.
46. Yunis JJ, Bloomfield CD, Ensrud K. All patients with acute non lymphocytic leukaemia may have a chromosomal defect. Engl J med 1981;305:135-9.
47. Bernard OA, Berger R. Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromosomes Cancer 1995 jun; 13(2):75-85.
48. Larson RA, Le Beau MM, Ratain MJ, Rowley JD. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukaemia. Blood 1992;79:1892-3.
49. Bloomfield CD, Archer KJ, Mrozek K, Lillington DM, Kaneko Y, Head DR, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukaemia: report from an international workshop. Genes Chromosomes Cancer 2002 apr;33(4):362-78.
50. Berger R. Gènes à multipartenaires et remaniements chromosomiques des hémopathies malignes. Ann Genet 1999;42(1):21-32.
51. Harrison CJ, Cuneo A, Clark R, Johansson B, Lafage-Pochitaloff M, Mugneret F, et al. Ten novel 11q23 chromosomal partner sites. Leukaemia 1998;12:811-22.
52. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, et al. All patients with the t(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997;90(2):535-41.
53. Sano K. Structure of AF3p21, a new member of mixed lineage leukaemia (MLL) fusion partner proteins-implication for MLL-induced leukemogenesis. Leuk Lymphoma 2001;42:595-602
54. Huret JL. Atlas Genet Cytogenet Oncol Haematol.http: //www.infobiogen.fr/services/chromcancer.
55. Van Limbergen H, Poppe B, Janssens A, De Bock R, De Paepe A, Noens L, et al. Molecular cytogenetic analysis of 10;11 rearrangements in acute myeloid leukaemia. Leukaemia 2002;16:344-51.
56. Chaplin T, Jones L, Debernardi S, Hill AS, Lillington DM, Young BD. Molecular analysis of the genomic inversion and insertion of AF10 into MLL suggests a single-step event. Genes Chromosomes Cancer 2001 feb;30(2):175-80.
57. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukaemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukaemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002 jul 15;62(14):4075-80.
58. Hayette S, Tigaud I, Vanier A, Martel S, Corbo L, Charrin C, et al. AF15q14, a novel partner gene fused to the MLL gene in an acute myeloid leukaemia with a t(11;15)(q23;q14). Oncogene 2000 sep 7;19(38):4446-50.
59. Megonigal MD, Cheung NK, Rappaport EF, Nowell PC, Wilson RB, Jones DH, et al. Detection of leukaemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci USA 2000 mar 14;97(6):2814-9.
60. Osaka M, Rowley JD, Zeleznik-Le NJ. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukaemia with a t(11;17)(q23;q25). Proc Natl Acad Sci USA 1999 may 25;96(11):6428-33.
61. Beverloo HB, Le Coniat M, Wijsman J, Lillington DM, Bernard O, de Klein A, et al. Breakpoint heterogeneity in t(10;11) translocation in AML-M4/M5 resulting in fusion of AF10 and MLL is resolved by fluorescent in situ hybridization analysis. Cancer Res 1995 oct. 1;55:4220-4.
62. Bernard O. Implication du gène HRX dans les anomalies de la région chromosomique 11q23 des hémopathies malignes. Hématologie 1997;3(suppl. au n° 2):102-5.
63. Dohner K, Tobis K, Ulrich R, Frohling S, Benner A, Schlenk RF, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60-years-old with acute myeloid leukaemia and normal cytogenetics: a study of the Acute Myeloid Leukaemia Study Group Ulm. J Clin Oncol 2002 aug. 1;20(15):3254-61.
64. Michaux L, Wlodarska I, Stul M, Dierlamm J, Mugneret F, Herens C. MLL amplification in myeloid leukaemias: A study of 14 cases with multiple copies of 11q23. Genes Chromosomes Cancer 2000;1:40-7.
65. Harbott J, Mancini M, Verellen-Dumoulin C, Moorman AV, Secker-Walker LM. Hematological malignancies with a deletion of 11q23: cytogenetic and clinical aspects. European 11q23 Workshop participants. Leukaemia 1998 may; 12(5):823-7.
66. Abdou SM, Jadayel DM, Min T, Swansbury GJ, Dainton MG, Jafer O, et al. Incidence of MLL rearrangement in acute myeloid leukaemia, and a Calm-AF10 fusion in M4 type acute myeloblastic leukaemia. Leuk Lymphoma 2002 jan;43 (1):89-95.
67. Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, et al. Biology and outcome of childhood acute megakaryoblastic leukaemia: a single institution's experience. Blood 2001;97(12):3727-32.
68. Dastugue N, Lafage-Pochitaloff M, Pagès MP, Radford I, Bastard C, Talmant P, et al. Cytogenetic profile of childhood and adult megakaryoblastic leukaemia (M7): a study of the Groupe français de cytogéné tique hématologique (GFCH). Blood 2002;100(2):618-26.
69. Mercher T, Busson-Le Coniat M, Monni R, Mauchauffe M, Khac FN, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukaemia. Proc Natl Acad Sci USA 2001;98(10):5776-9.
70. Mercher T, Busson-Le Coniat M, Khac FN, Ballerini P, Mauchauffe M, et al. Recurrence of OTT-Mal fusion in t(1;22) of infant AML-M7. Genes Chromosomes Cancer 2002;33:22-8.
71. Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, et al. Structural rearrangements of chormosome 3 in 57 patients with acute myeloid leukaemia: clinical, hematological and cytogenetic features. Hematol J 2002;3:21-31.
72. Secker-Walker LM, Mehta A, Bain B, on behalf of the UKCCG. Abnormalities of 3q21 and 3q26 in myeloide malignancy: a United Kingdom Cancer Cytogenetic Group Study. Br J Haematol 1995;91:490-501.
73. Testoni N, Borsaru G, Martinelli G, Carboni C, Ruggeri D, Ottaviani E, et al. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukaemia: biological and clinical features. Haematologica 1999;84:690-4.
74. Mochizuki N, Shimizu S, Nagasawa T, Tanaka H, Taniwaki M, Yokota J, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EV11 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukaemia cells. Blood 2000;96(9):3209-14.
75. Pebusque MJ, Chaffanet M, Popovici C, Birnbaum D. FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12. Bull Cancer 2000;87:887-94.
76. Brown J, Jawad M, Twigg SR, Saracoglu K, Sauercoglu K, Sauerbrey A, et al. A cryptic t(5;11)(q35;p15.5) in 2 children with acute myeloid leukaemia with apparently normal karyotypes, identified by a multiplex fluorescence in situ hybridization telomere assay. Blood 2002;99(7):2526-31.
77. Jaju RJ, Fidler C, Haas OA, Strickson AJ, Watkins F, Clark K, et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukaemia. Blood 2001 Aug 15;98(4): 1264-7.
78. Nakamura T, Yamazaki Y, Hatano Y, Miura I. NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukaemia with chromosome translocation t(1;11)(q23;p15). Blood 1999 jul. 15;94(2): 741-7.
79. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukaemia. Cancer Res 1998 oct 1;58(19):4269-73.
80. Arai Y, Kyo T, Miwa H, Arai K, Kamada N, Kita K. Heterogenous fusion transcripts involving the NUP98 gene and HOXD13 gene activation in a case of acute myeloid leukaemia we the t(2;11)(q31; p15) translocation. Leukaemia 2000;14(9):1621-9.
81. Taketani T, Taki T, Shibuya N, Ito E, Kitazawa J, Terui K, et al. The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukaemia with t(2;11)(q31;p15) Cancer Res 2002 Jan 1;62(1):33-7.
82. Hussey DJ, Nicola M, Moore S, Peters GB, Dobrovic A. The (4;11) (q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukaemia. Blood 1999 sep. 15;94(6):2072-9.
83. Borrow J, Shearman AM, Stanton Jr VP, Becher R, Collins T, Williams AJ, et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet 1996 feb; 12(2):159-67.
84. Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 1996 feb;12(2):154-8.
85. Ahuja HG, Popplewell L, Tcheurekdjian L, Slovak ML. NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukaemia. Gens Chromosomes Cancer 2001;30(4):410-5.
86. Takenati T, Taki T, Ono R, Kobayashi Y, Ida K, Hayashi Y. The chromosome translocation t(7;11)(p15;p15) in acute myeloid leukaemia results in fusion of the NUP98 gene with a HOXA cluster gene, HOXA13, but not HOXA9. Genes Chromosomes Cancer 2002;34:437-43.
87. Rosati R, La Starza R, Veronese A, Aventin A, Schwienbacher C, Valle T. NUP98 is fused to the NSD3 gene in acute myeloid leukaemia associated with t(18;11)(p11.2;p15). Blood 2002;99(10):3857-60.
88. Hussey DJ, Moore S, Nicola M, Dobrovic A. Fusion of the NUP98 gene with the LEDGF/p52 gene defines a recurrent acute myeloid leukaemia translocation. BMC Genet 2001;2(1):20.
89. Arai Y, Hosoda F, Kobayashi H, Arai K, Hayashi Y, Kamada N, et al. M. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10. Blood 1997 jun. 1;89(11):3936-44.
90. Panagopoulos I, Isaksson M, Billstrom R, Strombeck B, Mitelman F, Johansson B. Fusion of the NUP98 gene and the homeobox gene HOXC13 in acute myeloid leukaemia with (11;12)(p15;q13). Genes Chromosomes Cancer 2003 jan; 36(1):107-12.
91. Ahuja HG, Felix CA, Aplan PD. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood 1999 nov. 1;94(9): 3258-61.
92. Streubel B, Sauerland C, Heil G, Freund M, Bartels H, Lengfelder E, et al. Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL or MDS and abnormalities of the short arm of chromosome 12. Br J Haematol 1998;100:521-33.
93. Simmons HM, Oseth L, Nguyen P, O'Leary M, Conklin KF, Hirsch B. Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML. Leukaemia 2002 dec; 16(12):2408-16.
94. Odero MD, Vizmanos JL, Roman JP, Lahortiga I, Panizo C, Calasanz MJ, et al. A novel gene, MDS2, is fused to ETV6/Tel in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer 2002;35:11-9.
95. Berger R, Le Coniat M, Lacronique V, Daniel MT, Lessard M, Berthou C, et al. Chromosome abnormalities of the short arm of chromosome 12 in hematopoietic malignancies: a report including 3 novel translocations involving the Tet/ETV6 gene. Leukaemia 1997;11:1400-3.
96. Salomon-Nguyen F, Della-Valle V, Mauchauffe M, Busson-Le Coniat M, Ghysdael J, Berger R, et al. The t(1;12)(q211;p13) translocation of human acute myeloblastic leukaemia results in a Tel-ARNT fusion. Proc Natl Acad Sci USA 2000 jun. 6;97(12):6757-62.
97. Cazzaniga G, Tosi S, Aloisi A, Giudici G, Daniotti M, Pioltelli P, et al. The tyrosine kinase ABL-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood 1999;15(94):4370-3.
98. Iijima Y, Ito T, Oikawa T, Eguchi M, Eguchi-Ishimae M, Kamada N, et al. A new ETV6/Tel partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25; p13) translocation. Blood 2000;15(95):2126-31.
99. Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CD, Dainton M, et al. Fluorescence in situ hybridization analysis of t(3;12) (q26;p13): a recurring chromosomal abnormality involving the Tel gene (ETV6) in myelodysplastic syndromes. Blood 1996;88:682-9.
100. Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, et al. Fusion of ETV6 to MDS1/Evi1 as a result of t(3;12) (q26;p13) in myeloproliferative disorders. Cancer Res 1997 feb. 15;57(4):564-9.
101. Cools J, Bilhou-Nabera C, Wlodarska I, Cabrol C, Talmant P, Bernard P, et al. Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukaemias with a t(4;12)(q11-q12;p13) Blood 1999 sep. 1;94(5): 1820-4.
102. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, Tel, in chronic myelomonocytic leukaemia with t(5;12) chromosomal translocation. Cell 1994 apr. 22;77(2):307-16.
103. Beverloo HB, Panagopoulos I, Isaksson M, van Wering E, van Drunen E, de Klein A, et al. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukaemias with the t(7;12) (q36;p13). Cancer Res 2001 Jul 15;61:5374-7.
104. Chase A, Reiter A, Burci L, Cazzaniga G, Biondi A, Pickard J, et al. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukaemia with the t(12;13)(p13;q12). Blood 1999 feb. 1;93(3):1025-31.
105. Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukaemia with t(12;15)(p13;q25). Blood 1999 feb. 15;93(4):1355-63.
106. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, et al. Fusion of the Tel gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukaemia. Proc Natl Acad Sci USA 1995 may 23;92(11):4917-21.
107. Buijs A, van Rompaey L, Molijn AC, Davis JN, Vertegaal AC, Potter MD, et al. The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukaemia, is a transcription factor with transforming activity. Mol Cell Biol 2000 dec;20(24):9281-93.
108. Mitelman F, Johansson B, Mertens FE. Mitelman database of chromosome aberrations in cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman. 2001.
109. Salomon-Nguyen F, Busson-Le Coniat M, Lafage Pochitaloff M, Mozziconacci J, Berger R, Bernard OA. AML1-MTG16 fusion gene in therapy-related acute leukaemia with t(16;21)(q24;q22): 2 new cases. Leukaemia 2000;14:1704-5.
110. Hromas R, Busse T, Carroll A, Mack D, Shopnick R, Zhang DE, et al. Fusion AML1 transcript in a radiation-associated leukaemia results in a truncated inhibitory AML1 protein. Blood 2001;97(7):2168-70.
111. Duchayne E, Dastugue N, Kuhlein E, Huguet F, Pris J. De novo acute leukaemia with a sole 5q-: morphological, immunological, and clinical correlations. Leuk Lymphoma 1993 nov;11(5-6):387-92.
112. Lessard M, Herry A, Berthou C, Leglise MC, Abgrall JF, Morice P, et al. Investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes. Leuk Res 1998;22:303-12.
113. Hu Z, Gomes I, Horrigan SK, Kravarusic J, Mar B, Arbieva Z, et al. A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukaemia tumor suppressor gene on chromosome 5 band q31. Oncogene 2001 oct. 18;20(47):6946-64.
114. Dubourg C, Toutain B, Helias C, Henry C, Lessard M, Le Gall JY, et al. Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene. Cancer Genet Cytogenet 2002 apr. 1;134:33-7.
115. Le Beau MM, Espinosa R, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996 sep. 15;88(6):1930-5.
116. Kratz CP, Emerling BM, Bonifas J, Wang W, Green ED, Beau MM, et al. Genomic structure of the P1K3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood 2002 jan. 1;99(1):372-4.
117. Johansson B, Billstrom R, Kristoffersson U, Akerman M, Garwicz S, Ahlgren T, et al. Deletion of chromosome arm 3p in hematologic malignancies. Leukaemia 1997 aug;11(8):1207-13.
118. Odero MD, Carlson K, Calasanz MJ, Lahortiga I, Chinwalla V, Rowley JD. Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping. Genes Chromosomes Cancer 2001;31:134-42.
119. La Starza R, Wlodarska I, Aventin A, Falzetti D, Crescenzi B, Martelli MF, et al. Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. Blood 1998;9:231-7.
120. Soenen V, Preudhomme C, Roumier C, Daudignon A, Lai JL, Fenaux P. 17p Deletion in acute myeloid leukaemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998 feb. 1;91(3):1008-15.
121. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, et al. Myelodysplastic syndromes and acute myeloid leukaemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukaemia 1995 mar;9(3):370-81.
122. Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a Pac/Bac contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 2000 aug. 10;19(34):3902-13.
123. MacGrogan D, Alvarez S, DeBlasio T, Jhanwar SC, Nimer SD. Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukaemia cell lines. Oncogene 2001 jul. 12;20(31):4150-60.
124. Patsouris C, Michael PM, Campbell LJ. A new non-random unbalanced t(17;20) in myeloid malignancies. Cancer Genet Cytogenet 2002 oct. 1;138(1):32-7.
125. Mugneret F, Dastugue N, Favre B, Sidaner I, Salles B, Huguet-Rigal, et al. Der(16)t(1;16)(q11;q11) in myelody splastic syndromes: a new non-random abnormality characterized by cytogenic and fluorescence in situ hybridization studies. Br J Haematol 1995 may;90(1): 119-24.
126. Busson-Le Coniat M, Salomon-Nguyen F, Dastugue N, Maarek O, Lafage-Pochitaloff, et al. Fluorescence in situ hybridization analysis of chromosome 1 abnormalities in hematopoietic disorders: rearrangements of DNA satellite II and new recurrent translocations. Leukaemia 1999;13:1975-81.
127. Johansson B, Axelsson P, Billstrom R, Strombeck B, Arheden K, Olofsson T, et al. Isodicentric 7p, idic(7)(q11.2) in acute myeloid leukaemia associated with older age and favorable response to induction chemotherapy: a new clinical entity? Genes Chromosomes Cancer 2001 mar;30(3):261-6.
128. Heim S, Mitelman F. Secondary chromosome aberrations in the acute leukaemias. Cancer Genet Cytogenet 1986 aug;22(4):331-8.
129. Farag SS, Archer KJ, Mrozek K, Vardiman JW, Carroll AJ, Pettenati MJ, et al. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukaemia: results from Cancer and Leukaemia Group B 8461. Int J Oncol 2002 nov;21(5):1041-51.
130. Johansson B, Billstrom R, Mauritzson N, Mitelman F. Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasms. Cancer Genet Cytogenet 1994 may;74(1):62-5.
131. Mecucci C, Van Orshoven A, Tricot G, Michaux JL, Delannoy A, Van Den Berghe H. Trisomy 4 identifies a subset of acute nonlymphocytic leukaemias. Blood 1986;67:1328-32.
132. Paulsson K, Sall T, Fioretos T, Mitelman F, Johansson B. The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet 2001 Oct 15;130(2):160-5.
133. Wolman SR, Gundacker H, Appelbaum FR, Slovak ML, Southwest Oncology Group. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukaemia: a Southwest Oncology Group study. Blood 2002;100:29-35.
134. Lessard M, Herry A, Berthou C, Leglise MC, Abgrall JF, Luquet I, et al. Chromosome 8 tetrasomies and pentasomies - a clonal abnormality closely associated with acute monocytic leukaemia. Leuk Lymphoma 1997;27:127-35.
135. Yan J, Marceau D, Drouin R. Tetrasomy 8 is associated with a major cellular proliferative advantage and a poor prognosis. Two cases of myeloid hematologic disorders and review of the literature. Cancer Genet Cytogenet 2001 feb;125(1):14-20.
136. Kameoka J, Funato T, Obara Y, Kadowaki I, Yokoyama H, Kimura T, et al. Clonal evolution from trisomy into tetrasomy of chromosome 8 associated with the development of acute myeloid leukaemia from myelodysplastic syndrome. Cancer Genet Cytogenet 2001 jan. 15;124(2):159-64.
137. Gad SG, Callen DF, Kuss B, Downing JR, Behm F, Head D, et al. Identification of an inversion 16 coexisting with an isochromosome 22q by in situ hybridization in a case of childhood AML M4e. Leukaemia 1993 oct;7(10):1658-62.
138. Britton V, Kwan YL, White L, Yip MY. Trisomy 4 in a case of acute biphenotypic leukaemia. Cancer Genet Cytogenet 1990 jul. 15;47(2): 265-9.
139. Cox-Froncillo MC, Zollino M, Del Poeta G, Bajer J, Stasi R, Venditti A, et al. Trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukaemia with B lineage markers and in acute minimally differentiated myeloid leukaemia (MO). Cancer Genet Cytogenet 1995 mar;80(1):66-7.
140. Czepulkowski B, Powell AR, Pagliuca A, Mufti GJ. Trisomy 10 and acute myeloid leukaemia. Cancer Genet Cytogenet 2002 apr. 1;134(1):81-3.
141. Soni M, Brody J, Allen SL, Schulman P, Kolitz J, Rai K, et al. Clinical and morphological features of cases of trisomy 13 in acute nonlymphocytic leukaemia. Leukaemia 1996 apr;10(4):619-23.
142. Roumier C, Eclache V, Imbert M, Davi F, Macintyre E, Garand R, et al. Mo AML, clinical and biological features of the disease including AML1 gene mutations: a report of 59 cases by the Groupe francais d'hématologie cellulaire (GFHC) and the Groupe français de cytogénétique hématologique (GFCH). Blood 2002 oct. 10.
143. Alvarez S, MacGrogan D, Calasanz MJ, Nimer SD, Jhanwar SC. Frequent gain of chromosome 19 in megakaryoblastic leukaemias detected by comparative genomic hybridization. Genes Chromosomes Cancer 2001;32:285-93.
144. Fraisse J, Jaubert J, Goure D. les anomalies chromosomiques dans les leucémies aiguës granuleuses ou leucémies aiguës non lymphoïdes. ParhologBiol 1982;30:769-74.
145. Wiernik PH, Kim H, Gundacker, et al. Prognostic implication of additional cytogenetic aberrations in de novo acute myeloid leukaemia (AML) with t(15;17), t(8;21) or inv(16)t(16;16). Blood 2001;98:457a.